Effects of infectious mononucleosis and HLA-DRB1*15 in multiple sclerosis

Abstract

Background

Both human leukocyte antigen (HLA)-DRB1*15 and Epstein-Barr virus infection presenting as infectious mononucleosis (IM) are recognized as risk factors for multiple sclerosis (MS). However, their combined effect and possible interaction on MS risk is not known.

Objective

To assess the association between HLA-DRB1*15 and risk of MS in persons with and without IM.

Methods

We compared the prevalence of DRB1*15 in MS patients with (n = 76) and without (n = 1,836) IM with the corresponding distributions in blood donors with (n = 62) and without (n = 484) IM histories. This allowed us to estimate the relative risk of MS associated with DRB1*15 in the presence and absence, respectively, of previous IM. We then estimated the interaction between DRB1*15 and IM as the ratio of the two individual odds ratios.

Results

In IM-naïve individuals, DRB1*15 carried a 2.4-fold (95% confidence interval [CI], 2.0–3.0) increased MS risk. In contrast, among persons with IM history, DRB1*15 was associated with a 7.0-fold (95% CI, 3.3–15.4) increased MS risk. Thus, the MS risk conferred by HLA-DRB1*15 was 2.9 (95% CI, 1.3–6.5)-fold stronger in the presence than in the absence of IM. Combined with previous results, this result indicates that DRB1*15-positive persons with a history of IM may be at a 10.0-fold (95% CI, 6.0–17.9) increased risk of MS compared with persons who are DRB1*15 and IM-naïve.

Conclusion

DRB1*15 and IM may act in synergy causing MS.

Keywords

epidemiology HLA-DRB1*15 immunology infectious mononucleosis multiple sclerosis

Get full access to this article

View all access options for this article.

References

1 Jersild C Fog T Hansen GS Thomsen M Svejgaard A Dupont B . Histocompatibility determinants in multiple sclerosis, with special reference to clinical course. Lancet 1973; 2: 1221–1225.

2 Beall SS Biddison WE McFarlin DE McFarland HF Hood LE . Susceptibility for multiple sclerosis is determined, in part, by inheritance of a 175-kb region of the TcR V beta chain locus and HLA class II genes. J Neuroimmunol 1993; 45: 53–60.

3 de Jong BA Huizinga TW Zanelli E . Evidence for additional genetic risk indicators of relapse-onset MS within the HLA region. Neurology 2002; 59: 549–555.

4 Olerup O Hillert J . HLA class II-associated genetic susceptibility in multiple sclerosis: a critical evaluation. Tissue Antigens 1991; 38: 1–15.

5 Hafler DA Compston A Sawcer S . Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007; 357: 851–862.

6 Nielsen TR Rostgaard K Nielsen NM . Multiple sclerosis after infectious mononucleosis. Arch Neurol 2007; 64: 72–75.

7 Levin LI Munger KL Rubertone MV . Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. JAMA 2005; 293: 2496–2500.

8 Operskalski EA Visscher BR Malmgren RM Detels R . A case-control study of multiple sclerosis. Neurology 1989; 39: 825–829.

9 Lindberg C Andersen O Vahlne A Dalton M Runmarker B . Epidemiological investigation of the association between infectious mononucleosis and multiple sclerosis. Neuroepidemiology 1991; 10: 62–65.

10.

10 Martyn CN Cruddas M Compston DA . Symptomatic Epstein-Barr virus infection and multiple sclerosis. J Neurol Neurosurg Psychiatry 1993; 56: 167–168.

11.

11 Haahr S Koch-Henriksen N Moller-Larsen A Eriksen LS Andersen HM . Increased risk of multiple sclerosis after late Epstein-Barr virus infection: a historical prospective study. Mult Scler 1995; 1: 73–77.

12.

12 Marrie RA Wolfson C Sturkenboom MC . Multiple sclerosis and antecedent infections: a case-control study. Neurology 2000; 54: 2307–2310.

13.

13 Hernan MA Zhang SM Lipworth L Olek MJ Ascherio A . Multiple sclerosis and age at infection with common viruses. Epidemiology 2001; 12: 301–306.

14.

14 Haahr S Plesner AM Vestergaard BF Hollsberg P . A role of late Epstein-Barr virus infection in multiple sclerosis. Acta Neurol Scand 2004; 109: 270–275.

15.

15 Goldacre MJ Wotton CJ Seagroatt V Yeates D . Multiple sclerosis after infectious mononucleosis: record linkage study. J Epidemiol Community Health 2004; 58: 1032–1035.

16.

16 Lang HL Jacobsen H Ikemizu S . A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat Immunol 2002; 3: 940–943.

17.

17 Koch-Henriksen N . The Danish Multiple Sclerosis Registry: a 50-year follow-up. Mult Scler 1999; 5: 293–296.

18.

18 Fagius J . [Disease-modifying treatment of MS–progress with complications] Lakartidningen 2003; 100: 1164 , 1167–1168.

19.

19 Hjalgrim H Askling J Sorensen P . Risk of Hodgkin's disease and other cancers after infectious mononucleosis. J Natl Cancer Inst 2000; 92: 1522–1528.

20.

20 Oturai A Larsen F Ryder LP . Linkage and association analysis of susceptibility regions on chromosomes 5 and 6 in 106 Scandinavian sibling pair families with multiple sclerosis. Ann Neurol 1999; 46: 612–616.

21.

21 Akesson E Oturai A Berg J . A genome-wide screen for linkage in Nordic sib-pairs with multiple sclerosis. Genes Immun 2002; 3: 279–285.

22.

22 Dunbar SA . Applications of Luminex xMAP technology for rapid, high-throughput multiplexed nucleic acid detection. Clin Chim Acta 2006; 363: 71–82.

23.

23 Piegorsch WW Weinberg CR Taylor JA . Non-hierarchical logistic models and case-only designs for assessing susceptibility in population-based case-control studies. Stat Med 1994; 13: 153–162.

24.

24 De Jager PL Simon KC Munger KL Rioux JD Hafler DA Ascherio A . Integrating risk factors: HLA-DRB1*1501 and Epstein-Barr virus in multiple sclerosis. Neurology 2008; 70: 1113–1118.

25.

25 Nielsen TR Pedersen M Rostgaard K Frisch M Hjalgrim H . Correlations between Epstein-Barr virus antibody levels and risk factors for multiple sclerosis in healthy individuals. Mult Scler 2007; 13: 420–423.

26.

26 Ascherio A Munger KL Lennette ET . Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA 2001; 286: 3083–3088.

27.

27 DeLorenze GN Munger KL Lennette ET Orenstreich N Vogelman JH Ascherio A . Epstein-Barr virus and multiple sclerosis: evidence of association from a prospective study with long-term follow-up. Arch Neurol 2006; 63: 839–844.

28.

28 Larsen PD Bloomer LC Bray PF . Epstein-Barr nuclear antigen and viral capsid antigen antibody titers in multiple sclerosis. Neurology 1985; 35: 435–438.

29.

29 Oldstone MB . Molecular mimicry and autoimmune disease. Cell 1987; 50: 819–820.

30.

30 Ythier A Moreau JF Peyrat MA Bignon JD Soulillou JP . HLA-AB and -DR types in patients with infectious mononucleosis (IM). Tissue Antigens 1983; 21: 329–332.

31.

31 Ebers GC . Prognostic factors for multiple sclerosis: the importance of natural history studies. J Neurol 2005; 252(Suppl. 3): iii15–iii20.

32.

32 Masterman T Ligers A Olsson T Andersson M Olerup O Hillert J . HLA-DR15 is associated with lower age at onset in multiple sclerosis. Ann Neurol 2000; 48: 211–219.

33.

33 Hensiek AE Sawcer SJ Feakes R . HLA-DR 15 is associated with female sex and younger age at diagnosis in multiple sclerosis. J Neurol Neurosurg Psychiatry 2002; 72: 184–187.

34.

34 Smestad C Brynedal B Jonasdottir G . The impact of HLA-A and -DRB1 on age at onset, disease course and severity in Scandinavian multiple sclerosis patients. Eur J Neurol 2007; 14: 835–840.

35.

35 Kantarci OH . de, AM, Weinshenker, BG. Identifying disease modifying genes in multiple sclerosis. J Neuroimmunol 2002; 123: 144–159.

36.

36 Edgren G Tran TN Hjalgrim H . Improving health profile of blood donors as a consequence of transfusion safety efforts. Transfusion 2007; 47: 2017–2024.

37.

37 Tiitinen S Kaarela K Filipowicz-Sosnowska A . HLA typing and seropositivity in Finnish and in Polish patients with rheumatoid arthritis and amyloidosis. Clin Rheumatol 1992; 11: 265–268.

38.

38 Schipper RF D'Amaro J Bakker JT Bakker J van Rood JJ Oudshoorn M . HLA gene haplotype frequencies in bone marrow donors worldwide registries. Hum Immunol 1997; 52: 54–71.